Table 4.
Review of literature on SBRT
| Authors | Study | Localization | Nr. of Lesions | Nr. of Fractions | Total Dose (Gy) | LC @ 1 year | Median OS (months) | Late Toxicity |
|---|---|---|---|---|---|---|---|---|
| Tse [34] | P | IHCC EHCC |
10 0 |
6 | 28-48 | 65% | 15 | 1 biliary obstruction 1 bowel obstruction |
| Goodman [29] | P | IHCC EHCC |
5 0 |
1 | 18-30 | 77% | 28.6 | None |
| Polistina [28] | R | IHCC EHCC |
0 10 |
3 | 30a | 80%b | 35.5 | 1 ulceration 2 stenosis |
| Ibarra [35] | R | IHCC EHCC |
11 0 |
3 | 22-50 | 55.5% | 11 | 3 Grad 3 |
| Barney [36] | R | IHCC EHCC |
6 4 |
3-5 | 45-60 | 100% | 15.5 | 1 Grade 3 biliary stenosis, 1 Grade 5 liver failure |
| Momm [22] | R | IHCC EHCC |
0 13 |
10-12 | 32-56 | 78% | 33.5 | 1 Grade 3 5 cholangitis |
| Weiner [37] | P | IHCC EHCC |
12 0 |
5 | 40-55 | 91%§ | 13.2 | 1 hepatic failure§ 1 biliary stricture |
| Kopek [27] | R | IHCC EHCC |
26 1 |
3 | 45 | 85% | 10.6 | 6 ulcerations 3 stenosis |
| Mahadevan [30] | R | IHCC EHCC |
31 11 |
3-5 | 24-45 | 88% | 17 | 4 Grade 3 (ulceration, cholangitis, abscess) |
| Sandler [26] | R | IHCC EHCC |
6 25 |
5 | 40 | 78% | 15.7 | 5 Grade ≥ 3 |
| Jung [25] | R | IHCC EHCC |
33 25± |
1-5 | 15-60 | 85% | 10 | 6 Grade 3 (ulceration, cholangitis, stenosis, perforation) |
| Current | R | IHCC EHCC |
17 26 |
3-12 | 21-66 | 78% | 14 | 3 Grade ≥ 3 |
R retrospective, P prospective, IHCCC intrahepatic cholangiocarcinoma, EHCCC extrahepatic cholangiocarcinoma
aconcurrent Gemcitabine
blocal response ratio
± 5 patients treated with conventional fractionation with a stereotactic boost
§In this study SBRT was performed also in patients with hepatocellular carcinoma. LC and toxicities are reported for the whole group of patients including hepatocellular and cholangiocarcinoma